Levamisole-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis in paediatric nephrotic syndrome: dose-dependent and idiosyncratic risks in paediatric patients.

BMJ Case RepSep 5, 2026 (epub)

Neha Thakur Rai, Narendra Rai

✦ AI-curated · Sources linked

Case in brief

Two pediatric cases of levamisole-induced vasculitis are reported, highlighting the risks associated with this medication in managing nephrotic syndrome. The first case involved a female child who developed multisystemic vasculitis after an accidental dose increase, while the second case presented with similar symptoms after prolonged stable therapy. Both cases showed anti-neutrophil cytoplasmic antibodies and resolved upon drug withdrawal.

Diagnostic / clinical pearl

Clinicians should be vigilant for signs of levamisole-induced autoimmunity in pediatric patients, as it can occur with both dose escalation and prolonged therapy.

Why it matters

These cases illustrate that levamisole-induced vasculitis can affect diverse pediatric populations, emphasizing the need for careful monitoring regardless of treatment context.

Source

Published in BMJ Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.